Multifunctional bioactive glass and glass-ceramic biomaterials with antibacterial properties for repair and regeneration of bone tissue by Fernandes, J.S. et al.
This is a repository copy of Multifunctional bioactive glass and glass-ceramic biomaterials 
with antibacterial properties for repair and regeneration of bone tissue.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/127685/
Version: Accepted Version
Article:
Fernandes, J.S., Gentile, P., Pires, R.A. et al. (2 more authors) (2017) Multifunctional 
bioactive glass and glass-ceramic biomaterials with antibacterial properties for repair and 
regeneration of bone tissue. Acta Biomaterialia, 59. pp. 2-11. ISSN 1742-7061 
https://doi.org/10.1016/j.actbio.2017.06.046
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Multifunctional Bioactive Glass and Glass-Ceramic Biomaterials with 
Antibacterial Properties for Repair and Regeneration of Bone Tissue 
João S. Fernandes1,3, Piergiorgio Gentile2, Ricardo A. Pires1,3*, Paul V. Hatton2*, Rui 
L. Reis1,3 
1
 %¶V5HVHDUFK*URXS- Biomaterials, Biodegradables and Biomimetics, University 
of Minho, Headquarters of the European Institute of Excellence on Tissue 
Engineering and Regenerative Medicine, Parque da Ciência e Tecnologia, Zona 
Industrial da Gandra, 4805-017 Barco, GMR, Portugal 
2
 Bioengineering and Health Technologies Research Group, School of Clinical 
Dentistry, University of Sheffield, Claremont Crescent, Sheffield S10 2TA, United 
Kingdom 
3
 ,&96%¶V- PT Government Associate Laboratory, Braga/Guimarães, Portugal 
* Corresponding Authors: 
Ricardo A. Pires. E-mail: rpires@dep.uminho.pt 
Tel: +351 253 510 907 
Fax: +351 253 510 909  
and 
Prof Paul V. Hatton. E-mail: paul.hatton@sheffield.ac.uk 
Tel: +44 (0) 114 271 7938 
Fax: +44 (0) 114 226 5484  
Abstract 
Bioactive glass and related glass-ceramics have been used in bone tissue repair for 
over 30 years, and many of the features that relate to their bone bonding 
characteristics are relatively well understood. More recently, attention has focused on 
the development of advanced compositions to not only enhance this osteogenic 
behaviour but also impart other characteristics such as antimicrobial activity. The aim 
of this review is therefore to consider how inorganic modifications to bioactive 
glasses and glass-ceramics may be used to introduce greater biofunctionality towards 
the creation of a new generation of versatile, multifunctional materials for health. 
 
  
1. Introduction 
Multiple degenerative and inflammatory joint and bone diseases affect millions of 
people worldwide. In fact, in 2007 WKH%RQHDQG-RLQW'HFDGH¶V association predicted 
that the percentage of people over 50 years of age affected by bone diseases will 
double by 2020 [1]. The huge increase in joint and bone implant surgeries parallels 
that of medical-device associated infections [2, 3]. Bacterial infections associated 
with contamination of implanted medical-devices are a critical complication that often 
leads to the failure of the implant with significant impact concerning public health in 
developed countries [4, 5]. Moreover, the management of medical-device associated 
infections often requires the need for surgical intervention or/and prolonged usage of 
intravenous or oral antibiotic therapies leading to bone loss and significant morbidity 
resulting in severe limitations to the patients regarding normal life and wellbeing [6, 
7]. 
Furthermore, there is a desire to limit the use of antibiotics in a hospital setting and 
reduce the risk of encouraging the growth of drug-resistant microorganisms. Several 
pathogenic microorganisms (predominantly Staphylococcus aureus, Staphylococcus 
epidermidis, Escherichia coli and Pseudomonas aeruginosa) have been identified at 
the site of approximately 90% of all implants, and many of these organisms showed 
drug-resistance [5, 8, 9]. Moreover, the critical complications of bacterial 
contamination are mostly related with the adhesion of bacteria to the medical device, 
which aggregates in a hydrated polymeric matrix of their own synthesis to form 
biofilms [10-12]. These multifaceted structure made from microorganism and 
extracellular matrix is capable of resisting antibiotics and antibacterial agents being at 
the root of many persistent and chronic bacterial infections [13].  
Therefore, conventional therapy with systemic antibiotics is expensive and often 
unsuccessful. It presents poor antimicrobial dispersal at the site of infection due to 
limited blood circulation to infected skeletal tissue [14]. Several glass and glass-
ceramic biomaterials where successfully tested against bacterial biofilm. Valappil et 
al. [15] used phosphate-based glasses combined with gallium and silver for controlled 
delivery against oral biofilm models with success. While, Mulligan et al. [16] studied 
the effect of Na2O±CaO±P2O5 system doped with increasing amounts of copper on in 
vitro biofilm of Streptococcus sanguis for potential application as antibacterial agents 
for oral infections. 
While there is undoubtedly a growing clinical need for antimicrobial devices, the 
regulatory environment makes it increasingly difficult to bring these to market. Major 
pharmaceutical companies with research and development potential to make progress 
are also losing interest in the antibiotics market. The Food and Drug Administration 
(FDA) is approving increasingly fewer antibiotics. Statistical analysis performed by 
the Center for Disease Dynamics, Economics & Policy (CDDEP) highlighted that 
only six antibiotics were approved in the period between 2010 and 2014, 10 fewer 
than in the four-year period between 1983 and 1987. Actually, many of the drugs 
approved by FDA in the 1980s and 1990s have since been taken off the market for a 
variety of reasons, including: safety, efficacy or lack of profit [17]. Additionally, 
antibiotics are not an ideal solution due to challenges in reaching the target organisms, 
especially when these become associated with a medical device [18]. Local and/or 
preventive treatments may therefore be a superior approach to combat bacterial 
infections. Allan et al. [19] tested with success the use of 45S5 bioglass® to inhibit 
certain oral bacteria (including Streptococcus sanguis, Streptococcus mutans and 
Actinomyces viscosus) while repairing periodontal defects. Whereas, Brauer et al. [20] 
developed a strontium-releasing injectable bone cement with antibacterial activity 
against S. aureus and Streptococcus faecalis for the treatment of osteoporosis-related 
vertebral compression fracture. 
Therefore, after several years of improving surgical procedures, implementing strict 
and efficient antiseptic pro-operative and intra-operative procedures [18]. There is a 
growing interest in the investigation and development of smart and suitable 
biomaterials for bone and joint replacement with bioresorbable, biocompatible and 
bone bonding properties that are simultaneously effective treating implant-related 
bone infections. Different methods of loading implantable materials are been applied 
to for local antibiotic application [21-24]. But, manufactures are focusing their efforts 
to improve existing active ingredients for new applications instead of developing new 
compounds. Among them, multifunctional glass and glass-ceramic biomaterials have 
found extensive application as an orthopaedic and dental graft material as well as 
tissue engineering scaffolds [25-28]. Rahaman et al. have summarised part of the 
field, but they limited their review to a narrow range of papers and did not consider 
more detailed or complex aspects of glass design and structure-properties 
relationships [29]. 
Since 1969, Hence [30] and their co-workers were largely responsible for the 
development of bioactive glasses and study their bone bonding properties. More 
recently, work in this field was comprehensively renewed by Rees Rawlings [31] in 
1993, which included a description of the key features and properties of bioactive 
glasses and their glass-ceramics derivatives. Silicate glasses, the most used bioactive 
glasses, are well studied to form of a bone-like hydroxyapatite (HA) layer that is 
fundamental for a strong interfacial bond between implants and bone [30, 32]. 
Though, a slow degradation rate is their major drawback, making it difficult to match 
their degradation rate with the rate of new tissue formation, also presenting an 
incomplete HA conversion [33-35]. Outstandingly, the addition of borate to the glass 
network for the formation of borosilicate bioactive glasses has the potential to 
increase bio-degradation and conversion to HA [35-37]. Borosilicate bioactive glasses 
offer a more controlled dissolution rate that triggers a range of biological responses 
required for the final implantable biomaterial [38]. A number of parameters might 
influence the design of antibacterial bioactive glass. Undoubtedly, addition of specific 
ions (e.g. Ag+, Ce3+, Cu+) had demonstrated antimicrobial properties [16, 39-42]. 
Balamurugan et al. [40] reported the antibacterial properties of silver-incorporated 
bioactive glass system against E. coli attributed to the leaching of Ag+ ions from the 
glass matrix. Although there are other properties related with the network disruption 
that originate antimicrobial properties (e.g. pH, osmolarity, particle size and 
morphology) [19, 43-45]. For instance, Hu et al. [45] described antibacterial activity 
of 45S5 bioglass® against S. aureus, S. epidermidis and E. coli and correlated it with 
high pH and morphology of the glass. Glass and glass-ceramic biomaterials can either 
possess intrinsic antibacterial properties or/and be designed to have enhanced activity 
against specific bacteria and be used according to their final application form, 
including scaffolds, fibres, hydrogels or injectable materials. 
The aim of this review is to consider recent advances in the development of 
antibacterial strategies for glass and glass-ceramic based biomaterials and identify 
those that appear to offer most promise for use in orthopaedics medical devices and 
related technologies. Particularly, to consider how inorganic modifications to glass 
and glass-ceramics can be used to introduce greater biofunctionality to create a new 
generation of versatile, multifunctional materials for health. 
2. Bioactive glass and glass-ceramic biomaterials 
Glass and glass-ceramic biomaterials are unique ion-containing matrixes that recently 
are being investigated for the prevention and treatment of bone infections.  Glass and 
glass-ceramic biomaterials are very well known for their bioactive properties, the 
ability of bonding bone tissue through complex reactions forming strong and 
harmonious interfaces between biomaterials and tissue [30] and also for having good 
biocompatibility with great inductive and conductive properties [30, 32, 46, 47]. They 
have been used in the form of particles, porous or dense scaffolds for orthopaedic 
surgery and dentistry for bone repairing [48]. Glass biomaterials can predominantly 
be fabricated either by the traditional melt-quench or sol-gel processes, where a 
number of simple compounds are able to solidify as a glass [40, 49]. The glass 
structure is composed of network formers (e.g. Si4+, B3+ and P3+), usually silica, 
which contributes to the network formation containing either intermediate oxides (e.g. 
Al3+, Zn2+, Mg2+) and/or network modifiers  (e.g. Sr2+, Ca2+, Na+). Intermediate 
oxides, depending on the composition of the glass, may play a network or disrupting 
function, while network modifiers disrupt the network and produce non-bridging 
oxygen ions. 
A second step of controlled heat treatment is necessary to obtain glass crystallisation 
forming glass-ceramic biomaterials [50] (REFP2). This second heat treatment that 
leads to crystallisation involves two stages, first a nucleation and then a crystal 
growth stage, which promote the re-arrangement of the glass structures generating a 
well-ordered and crystalline structure. However, not all glasses are able to undergo a 
controlled heat treatment and form glass-ceramics either because they are already too 
stable or too unstable and difficult to have a controlled heat treatment. Therefore, 
glasses and glass-ceramic biomaterials possess the same building units just arranged 
in many different patterns, which leads to different final properties. The work in this 
field was extensively revised by Hench et al. [30] and Rawlings et al. [31]. 
The mechanism of bioactivity and bone bonding has been extensively studied in vitro 
(immersion in SBF) and in vivo, mainly for 45S5 bioglass® and was discussed 
elsewhere [34, 46]. Thus, the bonding ability of glass and glass-ceramic biomaterials 
relies in the degradation process of the biomaterials and subsequent formation of a 
HA layer on their surface, which mimics that mineral bone composition, bonding 
firmly with living bone tissue. Briefly the process follows the succeeding steps, (1) 
dissolution of ions from the glass into the medium, (2) reaction of Ca2+ dissolved and 
(PO4)3- from the media and consequent precipitation of amorphous calcium phosphate 
(ACP) layer, (3) the pH unbalance and increased dissolution of ions supports the 
growth of ACP, and (4) ACP layer incorporates (OH)- and (CO3)2- from the media 
and crystallises as HA layer. 
The silicate-based glasses and glass ceramic biomaterials are commonly associated 
with slow degradation rates and incomplete conversion to HA. This might result in a 
mismatch of the degradation rate with the rate of new tissue formation and the 
presence of long-term unconverted glass and glass-ceramic biomaterials in human 
body [33-35, 51]. More recently, borate- and borosilicate-based glasses have been 
used with great potential to overcome silicate-based glasses [35-37]. Due to their 
lower chemical durability, borate- and borosilicate-based glasses present increased 
bio-degradation and more complete conversion to HA. Furthermore, boron is 
associated with bone healing, stimulating bone formation and maintenance and with 
the increase in bone resistance to fractures [52-54]. Thereby, the compositional 
flexibility is at most importance while designing a glass or glass-ceramic 
biomaterials. As already has been shown a controlled release of ions promotes HA 
formation leading a perfect osteointegration, while stimulating osteogenic functions 
of the surrounding cells [52, 55]. Specific trace amount of component ions (e.g. Ag+, 
Cu+, Sr2+, Zn2+ and Ce3+) incorporated and released in a controlled manner can trigger 
a range of different biological responses, particularly antimicrobial activity [39, 55, 
56]. 
As matter of fact, different inorganic modifications have been introduced by several 
researchers in order to achieve glass and glass-ceramic biomaterials (Figure 1) 
endowed with antibacterial properties, resulting either in intrinsic and/or enhanced 
antibacterial glass and glass-ceramic biomaterials. Figure 1 displays a wide variety 
approaches used to develop glass and glass-ceramic biomaterials. Those biomaterials 
can be applied through a diversity of final forms and materials depending on their 
application in the body. As shown by in Figure 1a, glasses can either be designed with 
inorganic species into the bulk glass network or surface modified after glass 
formation. Moreover, different temperature schedules can be used to induce a phase 
separation. This phase separation can create groups of specific ion components to be 
released at different rates, increasing biological properties. On the other hand, glasses 
can be submitted to controlled heat treatments, resulting in to a glass-ceramic 
biomaterial with different properties (Figure 1b). Different properties can be obtained 
either by inducing crystalline phases formation or by the formation of a residual glass 
in to the glass-ceramic structure providing different releasing profiles. 
 Figure 1 - Potential routes to enhance the antimicrobial properties of a) bioactive 
glasse and b) glass-ceramic biomaterials via inorganic modification at different sites. 
The following section will review the different glass and glass-ceramic biomaterials 
currently proposed to diminish the susceptibility of joint and bone implant surgeries 
to the development of infections. 
3. Composition and modifications 
Glass and glass-ceramic biomaterials that are design to have suitable properties for 
bone integration have been demonstrating antibacterial activity when specifically 
assessed (REF paper3) [19, 57-59]. This antibacterial activity has been generally 
attributed to release of ions to the reaction media and their effect in the local 
physiological environment (e.g. pH, osmolarity). Zhang et al. [57] have demonstrated 
that bioactive glasses without any special bactericidal ions exhibited antibacterial 
effects for a large selection of bacteria with a concentration-dependent manner. The 
authors correlated the antibacterial effects essentially with the increase of pH and also 
the concentration of alkali ions, in which the glass S53P4 inhibited all the bacteria 
tested with (e.g. E. coli, P. aeruginosa, Moraxella Catarrhalis, E. faecalis, S. 
epidermidis). Moya et al. [60, 61] studied the borosilicate glasses (SiO2±Na2O±CaO±
B2O3 system) with a high content of calcium oxide and found that Ca2+ concentration 
is related with biocide activity against Gram positive, negative bacteria. Several other 
authors also related the antibacterial effect of glass biomaterial with pH and ion 
concentrations [43, 58, 62]. This kind of activity based on intrinsic antibacterial 
properties mainly relies on the degradation of the network and their consequent 
effects on the surrounding environment. Therefore, it is of most importance to fully 
understand the mechanisms of glass structure formation and their effect on 
degradation (Figure 1) to specifically design glasses towards the final application.  
Another important issue regarding the final glass applications are the extreme local 
environment condition that can harm the host tissues. Often, glasses are associated to 
a certain degree of cytotoxicity of glass biomaterials, which can potentially affect host 
cell viability in cells surrounding the implant. For instance, large increases of pH can 
induce adverse tissue responses as well as the high local osmolarity variations can 
unbalance the perfect behaviour of cells. Bakry et al. [63] showed that some cytotoxic 
effects of 45S5 bioglass® were associated with its initially acidic. In these cases it 
might be beneficial to use of heat treatments in order to induce crystallisation of glass 
biomaterial forming a glass-ceramic biomaterial with different physico-chemical 
properties [50, 64]. Hurrell-Gillingham et al. [64] investigated the effects of 
devitrification of glass-ionomer cements from SiO2-Al2O3-P2O5-CaO-CaF2 system on 
glass-ceramic formation and in vitro biocompatibility and could improve theirs 
biological properties. 
Other intrinsic glasses and glass-ceramic biomaterials have been found to be effective 
against bacteria sessile communities that are at the root of many persistent and 
chronic bacterial infections. Allan et al. [65] showed that 45S5 bioglass® significantly 
lowered the viability of biofilms of S. sanguinis grown in respect to inert glass 
control. While, Batalu et al. [62] reported that although MgB2 nano or micropowders 
did not affected S. aureus biofilm formation, it strongly inhibited E. coli adhesion and 
viability. The authors related the activity mainly with pH and boron derivatives 
released. 
Although, intrinsic glass and glass-ceramic biomaterials activity is rarely highly 
specific and uniquely oriented towards prokaryotic cells. Then, antibacterial glass and 
glass-ceramic biomaterials can also be developed by the simple incorporation of 
specific metal ions with known antibacterial properties into inorganic materials. These 
specific metal ions (e.g. Ag+, Ce3+, Cu+, Zn2+, Sr2+) can either be incorporated into the 
bulk network of the glasses or at the surface (Figure 1). Within the last few years, a 
number of glass and glass-ceramic biomaterials have been developed specially 
designed to have antibacterial properties [16, 39, 41, 43]. The majority of the studies 
were carried out with silver doped glass biomaterials. For instance, Bellantone et al. 
[41] and Ahmed et al. [43] demonstrated that silver doped glass biomaterials 
presented not only bacteriostatic, but they also caused a rapid bactericidal action 
against E. coli, P. aeruginosa, and S. aureus. Bellantone et al. prepared their silica-
based Ag+ glass via an acid-catalysed sol-gel route and observed that the dissolution 
profiles of Ag+ from glasses were consistent with silver accumulation by the bacteria. 
While, Ahmed et al. prepared their phosphate-based Ag+ glass by melt quench 
technique verifying the increase of antibacterial activity with increasing Ag2O 
contents. 
Other metal ions referred as antibacterial where also studied. Mulligan et al. [16] used 
cooper doped glass biomaterials to combat S. sanguis biofilm found in oral cavity. 
They prepared phosphate-based glasses system doped with increasing amounts of 
copper by melt quench technique with capacity to decrease viability of S. sanguis 
biofilm. However after a time period it returned to levels similar to those of controls. 
Nell et al. [42] also prepared phosphate-based glasses containing copper in the final 
form of fibres. Those fibres were capable to reduce the number of viable S. 
epidermidis attached to the fibres and in the surrounding environment. Another well 
know metal, Zinc, was incorporated into sol±gel silica-nanoparticles showing well-
defined antimicrobial activity. Halevas et al. [66] tested different concentration of 
incorporated zinc against S. aureus, Bacillus subtilis, Bacillus cereus, E. coli, P. 
aeruginosa, Xanthomonas campestris bacteria exhibiting higher activity for higher 
concentrations. There are other rare metals, such as cerium and galium that were also 
tested for antibacterial properties. Goh et al. [39] have tested cerium doped glasses for 
their antibacterial properties. They reported significant improvements regarding the 
antibacterial properties against E. coli of silica based glasses with 5 mol% of Ce or 
higher. While Valappil et al. [15] tested phosphate-based glasses doped with gallium 
and silver to test their combined action. They showed that the simultaneous release of 
Ag+ and Ga3+ from the glass reduced Porphyromonas gingivalis biofilm growth with 
a maximum effect after 168 h. 
Different strategies other then specific ions incorporation and related with bone tissue 
engineering were also reviewed on this revision paper. Although the composition of 
the glass is the essence of the antibacterial properties modulating their rate of ions 
release and consequently osmolarity and pH at the reaction site, there are other 
features such as particle size and morphology that can alter the potency of those 
biomaterials. Mortazavi et al. [67] assessed the antibacterial effect of bioactive glass 
nanoparticles obtained by sol-gel technique reporting that the antibacterial activity 
was caused by a synergetic effect of high calcium concentration and alkaline pH 
level, which might have been improved by the particle size reduction. Compositions 
58S showed antibacterial activity against E. coli, P. aeruginosa, and S. aureus while 
63S exhibit activity only against E. coli, S. aureus DQG6GLGQ¶WVKRZDQ\DFWLYLW\ 
Some other studies reported the influence of particle size and morphology of glass 
and glass-ceramic biomaterials [44, 57]. For instance, Waltimo et al. [44] studied 
SiO2-Na2O-CaO-P2O5 nano bioactive glasses and the influence of more than ten-fold 
higher specific surface area in ionic release and antibacterial effects. They reported 
that the increase of surface area might induce a faster dissolution of alkaline species 
to the medium and therefore, increasing the pH of the medium. 
Enhanced glass and glass-ceramic biomaterials differ from intrinsic because they have 
one or more ions intentionally incorporated to add bactericidal properties. Bulk 
materials that exert an antibacterial action in the absence of modifications, such as 
loaded with bactericidal substances or coated with active functional molecules, can 
generally be described as intrinsically antibacterial. Table 1 summarises substituted 
bioactive glasses that reported antibacterial activity correlating them with their active 
factor. 
Table 1 - Example of ions substituted bioactive glasses that reported antibacterial 
activity. 
Active 
factor 
Glass system 
Organisms 
Ref 
Gram (-) Gram (+) 
Ag+ SiO2-CaO-P2O5-Ag2O 
E. coli - [40] 
P. aeruginosa S. aureus [41] 
E. coli S. aureus [68] 
P2O5-CaO-Na2O-Ag2O 
E. coli,  P. 
aeruginosa 
S. aureus [43] 
B2O3-Na2O-P2O5-Ag2O - 
Listeria 
monocytogenes 
[69] 
SiO2-Ag (ceramic) E. coli S. aureus [70] 
Ag2O-B2O3-SiO2-CaO E. coli S. aureus [71] 
SiO2-CaO-P2O5-Al2O3-
Na2O-K2O-Ag2O 
E. coli E. faecalis [56] 
Ag+ and 
pH 
CaO-SiO2-Ag2O E. coli S. aureus [72] 
Ag+ and 
Ga3+ 
CaO-Na2O-P2O5-Ga2O-
Ag2O 
biofilm (Streptococcus gordonii 
and P. gingivalis) [15] 
Ag+ and 
Zn2+ 
Ceramic doped with Ag-Zn E. coli - [73] 
Ce+ and 
pH 
SiO2-CaO-P2O5-Ce E. coli - [39] 
Cu+ 
Na2O-CaO-P2O5-Cu - 
biofilm (S. 
sanguis) [16] 
Na2O-CaO-P2O5-Cu - S. epidermidis [42] 
Si4+ and 
pH 
S53P4 E. coli - [74] 
Zn2+ 
SiO2-Zn NPs E. coli S. aureus [75] 
SiO2-Zn NPs 
E. coli, P. 
aeruginosa, X. 
campestris 
S. aureus, B. 
subtilis, B. 
cereus 
[66] 
[ions] 
and pH 45S5 bioglass
®
 
E. coli,  P. 
aeruginosa, 
Actinobacillus 
actinomycetemc
omitans, P. 
gingivalis, 
Fusobacterium 
S. sanguis, S. 
mutans, A. 
viscosus and E. 
faecalis 
[19, 
44, 
45] 
nucleatum 
biofilms (S. sanguis) [65] 
58S and 63S bioglass® 
E. coli, P. 
aeruginosa, 
Salmonella 
typhi 
S. aureus [67] 
S53P4 
Acinetobacter 
spp, 
Haemophilus 
influenza, 
Enterobacter 
aerogenes, M. 
catarrhalis, E. 
coli, P. 
aeruginosa 
S. epidermidis, 
E. faecalis 
[57, 
58, 
76] 
MgB2 E. coli S. aureus [62] 
Na2O-MgO-CaO-B2O3-
P2O3-SiO2/K2O/Al2O3 
Acinetobacter 
spp, H. 
influenza, E. 
coli, P. 
aeruginosa 
E. faecalis [57] 
Na2O-K2O-MgO-CaO-
P2O3-SiO2 
Acinetobacter 
spp, H. 
influenza, E. 
aerogenes, E. 
coli, P. 
aeruginosa 
S. epidermidis, 
E. faecalis [57] 
Na2O-K2O-MgO-CaO-
B2O3-P2O3-SiO2 
- S. epidermidis [58] 
P2O5-CaO-Na2O E. coli, P. 
aeruginosa 
S. aureus [43] 
SiO2-B2O3-Na2O-MgO/SrO P. aeruginosa S. epidermidis Paper3 
[Ca2+] SiO2-B2O3-Na2O-CaO-K2O-Al2O3 
E. coli, P. 
aeruginosa 
S. aureus, S. 
epidermidis 
and 
Micrococcus 
[77] 
luteus 
SiO2-Na2O-CaO-P2O5-
Al2O3-
Fe2O/B2O3/K2O/MgO 
E. coli M. luteus, Candida kruse [61] 
SiO2-Na2O-CaO-B2O3/K2O-
Al2O3 
E. coli - [60] 
[Ca2+] 
and pH 
SiO2-CaO-Na2O-K2O-
P2O5/MgO 
- S. aureus [59] 
[Sr2+] SiO-SrO-CaF2-MgO - S. aureus, E. faecalis [20] 
pH CaO-SiO2 E. coli S. aureus [72] 
 
4. Mechanisms of action 
Composition is the basis of glass and glass-ceramic biomaterial properties. It can 
modulate the rate of ions release and consequently osmolarity and pH at the reaction 
site, influencing the physiological conditions at the implant surrounding. Therefore, 
glass and glass-ceramic biomaterials antibacterial activity is often engaged by their 
composition and dissolution properties [19, 65]. 
Recently, Echezarreta-LRғpez et al. [78] compiled from literature a large database on 
glass biomaterial production bacterial properties and experiments using an artificial 
intelligence tool, neurofuzzy logic technology. They verified that the antibacterial 
properties of glass and glass-ceramic biomaterials could be caused by the alkaline 
ions released, particularly calcium ions, and the increase of the pH of the medium. 
Briefly, the mechanisms of action of antibacterial glass and glass-ceramic 
biomaterials are by the: (i) release of ions that increases their (ii) osmolarity and (iii) 
pH at the reaction site, unbalancing the intracellular Ca2+, which results in to cell 
membrane depolarisation and their subsequent death. Cabal et al. [77] reported that 
borosilicate glass-ceramic biomaterials were able to inhibit bacterial growth, 
minimise bacterial adhesion and prevent biofilm formation by the perturbation of 
intracellular Ca2+ compartmentalisation, causing cytotoxicity and result in either 
apoptotic or necrotic bacteria cell death. This work tested the borosilicate glasses 
against five ATCC strains (S. aureus, S. epidermidis, P. aeruginosa, E. coli and 
Micrococcus lutea) with high percentages of bacterial cells reduction. 
However, there are several enhanced glass and glass-ceramic biomaterials that have 
their antibacterial activity based in the use of stable noble metals, such as silver 
(between many other: Ce3+, Cu+, Zn2+, Sr2+), which are acknowledged to have 
antibacterial activity [79]. Their antibacterial activity is oriented towards prokaryotic 
cells, often with specific activity. However, occasionally they are associated to a 
certain degree of cytotoxicity to animal cells [80]. Regarding antibacterial metals use, 
which is frequently active due to their corrosion in the physiological environment or 
the leaching to reaction medium, the high releasing concentration of ions might cause 
local toxicity. 
Even though the exact mechanism of metal ions regarding antibacterial action is still 
unknown it is recognised that it relies on a series of actions. Silver has been one of the 
earliest materials to be intentionally used in surgery for its bactericidal properties and 
the most studied. It acts by inactivating critical enzymes of the respiratory chain by 
biding to thiol groups and inducing hydroxyl radicals formation, creating oxidative 
stress [81]. Although other cellular components, like hydrogen bonding may also be 
involved that might implicate inhibition of bacterial cell wall synthesis, inhibition of 
protein synthesis, inhibition of synthesis of bacterial RNA and DNA, as well as 
inhibition of a metabolic pathway [81, 82]. Therefore, the activity is generally 
associated to the ionic form rather than to the elemental metal. Moreover, Jung el al. 
[81] studies demonstrated a higher antibacterial activity against gram-negative (E. 
coli) in respect to the gram-positive (S. aureus). This suggests that metal ions 
antibacterial activity might be related to the thickness of the peptidoglycan layer of 
gram-positive, which may difficult the action of the silver ions at the bacterial cell 
membrane. An overview of the hypothesised mechanisms associated with the 
antibacterial activity of metal particles is displayed in Figure 2. 
 
Figure 2 ± Overview of the hypothesised mechanisms associated with the antibacterial 
activity of metal particles. The most pronounced effects of silver ions is related with 
cellular metabolic activity (respiratory chain inhibition and cell pathways) as well as 
generation of ROS and damage DNA and RNA of bacteria. Diagram was modified 
from [83].  
5. Conclusions 
The growing impact of medical-device associated infections along with the efficacy 
loss of antibiotic common therapies are urging to find new preventive and treating 
strategies that costly and effectively combat this matter of concern. Bioactive glass 
and glass-ceramic biomaterials represent a powerful candidate to develop a 
biocompatible, osteointegrative biomaterial able to effectively treat implant-related 
bone infections. This review aimed to contribute to the development of the next-
generation of glass and glass-ceramic biomaterials that couples bone regenerative 
properties with intrinsic antibacterial activity relevant in the bone tissue engineering 
context. 
Herein was demonstrated that antibacterial glasse and glass-ceramic biomaterials are 
capable of supressing the growth of pathogenic organisms. While a number of 
classical compositions such as 45S5 bioglass® glass appear to have some 
antimicrobial activity, there is no doubt that enhanced composition are far more 
potent. For example, the addition of Ag+, Zn2+, Cu+, Ce3+ and Sr2+; all increased 
antimicrobial activity. While the presence of these specific ions had a direct effect on 
bacteria, it is important to note that other glass properties related to network 
disruption are also influenced by small compositional changes (i.e. pH, osmolarity, 
particle size). Having in consideration that these effects were frequently neglected by 
authors who often focused solely on the effects of specific ions. It is therefore 
recommended that glass and glass-ceramics scientists then pay more attention to the 
design of their biomaterials to aim an ideal system that provide a controlled local 
delivery of high concentrated antimicrobial compounds to the site of infection and 
simultaneously minimise risk of toxic effects while granting a structure that supports 
bone regeneration.  
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